MedPath

Rivastigmine

Generic Name
Rivastigmine
Brand Names
Exelon, Nimvastid, Prometax, Rivastigmine Sandoz, Rivastigmine 1 A Pharma, Rivastigmine Hexal, Rivastigmine Actavis
Drug Type
Small Molecule
Chemical Formula
C14H22N2O2
CAS Number
123441-03-2
Unique Ingredient Identifier
PKI06M3IW0
Background

Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

Indication

For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.

Associated Conditions
Dementia With Lewy Body Disease, Mild Dementia due to Parkinson's disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia, Moderate Dementia due to Parkinson's disease
Clinical Trials
Related News

Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles

Not Applicable
Conditions
Alzheimer's Disease
Interventions
First Posted Date
2014-02-14
Last Posted Date
2015-05-14
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
70
Registration Number
NCT02063269
Locations
🇰🇷

Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea, Republic of

16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients

Phase 4
Completed
Conditions
Alzheimer's Disease
Interventions
First Posted Date
2013-09-24
Last Posted Date
2017-02-13
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
222
Registration Number
NCT01948791
Locations
🇨🇳

Novartis Investigative Site, Beijing, China

Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease

Phase 4
Terminated
Conditions
Parkinson's Disease
Interventions
Drug: Placebo (for rivastigmine)
First Posted Date
2013-05-17
Last Posted Date
2018-10-09
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
91
Registration Number
NCT01856738
Locations
🇳🇱

Academic Medical Center, Amsterdam, Netherlands

🇳🇱

Atrium Medical Center, Heerlen, Netherlands

🇳🇱

University Medical Center St Radboud, Nijmegen, Netherlands

and more 1 locations

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
First Posted Date
2012-09-03
Last Posted Date
2017-05-30
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
542
Registration Number
NCT01677754
Locations
🇺🇸

Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States

🇨🇦

Vancouver Island Health Authority, Victoria, British Columbia, Canada

🇺🇸

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States

and more 139 locations

Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI

Phase 3
Completed
Conditions
Traumatic Brain Injury
Cognitive Impairment
Interventions
First Posted Date
2012-08-22
Last Posted Date
2018-02-27
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
94
Registration Number
NCT01670526
Locations
🇺🇸

Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States

🇺🇸

James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States

🇺🇸

VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States

and more 5 locations

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Phase 3
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Active Comparator
First Posted Date
2012-06-08
Last Posted Date
2016-08-01
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
216
Registration Number
NCT01614886
Locations
🇯🇵

Novartis Investigative Site, Shimonoseki-city, Yamaguchi, Japan

Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients

Not Applicable
Terminated
Conditions
Mild Cognitive Disorder
Mild Cognitive Impairment
Interventions
Drug: Placebo transdermal patch
First Posted Date
2012-05-18
Last Posted Date
2017-02-28
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
1
Registration Number
NCT01602198
Locations
🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia

Phase 4
Completed
Conditions
Alzheimer's Dementia
Interventions
First Posted Date
2012-04-25
Last Posted Date
2018-04-18
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
121
Registration Number
NCT01585272
Locations
🇨🇳

Novartis Investigative Site, Taipei, Taiwan

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Phase 4
Completed
Conditions
Alzheimer's Disease
Interventions
First Posted Date
2012-02-09
Last Posted Date
2016-11-18
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
52
Registration Number
NCT01529619
Locations
🇯🇵

Novartis Investigative Site, Kyoto, Japan

Mild Cognitive Impairment in Parkinson's Disease

Phase 4
Completed
Conditions
Parkinson's Disease
Mild Cognitive Impairment
Interventions
Drug: Placebo Patches
First Posted Date
2012-01-26
Last Posted Date
2017-04-07
Lead Sponsor
University of Pennsylvania
Target Recruit Count
28
Registration Number
NCT01519271
Locations
🇺🇸

University of Pennsylvania, Ralston House, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy